In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CEO Snapshots From The MedTech Forum

On The Agenda: Sustainability, Digital Integration And The Health Care Delivery Challenge

Executive Summary

Among the highlights of MedTech Europe’s annual MedTech Forum are the “unfiltered” views offered by company CEOs on the entire range of issues that influence decision-making or will have an impact on business operations in the near term.

You may also be interested in...



Bernasconi: Europe Needs A Better Strategic Rudder For Medtech Innovation Policy

Always ready to frame the needs of EU medtechs clearly and succinctly, MedTech Europe CEO Serge Bernasconi says that the local industry in the future could benefit from more strategic direction and support from a dedicated EU agency or similar tighter governance structure.

IHI: Europe’s Research And Innovation Project Is A Watchtower For Medtechs

April will see the first call for proposals under the Innovative Health Initiative, a patient-centric, demand-led project that is about to come to life for technology innovators after 30 months of negotiations and preparations by European health care industry associations and the European Commission.

The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’

The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV125097

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel